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Abstract
Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of the insulin signalling pathway. It has been demonstrated
that PTP1B deletion protects against the development of obesity and Type 2 Diabetes, mainly through its action on
peripheral tissues. However, little attention has been paid to the role of PTP1B in b-cells. Therefore, our aim was to study the
role of PTP1B in pancreatic b-cells. Silencing of PTP1B expression in a pancreatic b-cell line (MIN6 cells) reveals the
significance of this endoplasmic reticulum bound phosphatase in the regulation of cell proliferation and apoptosis.
Furthermore, the ablation of PTP1B is able to regulate key proteins involved in the proliferation and/or apoptosis pathways,
such as STAT3, AKT, ERK1/2 and p53 in isolated islets from PTP1B knockout (PTP1B 2/2) mice. Morphometric analysis of
pancreatic islets from PTP1B 2/2 mice showed a higher b-cell area, concomitantly with higher b-cell proliferation and a
lower b-cell apoptosis when compared to islets from their respective wild type (WT) littermates. At a functional level,
isolated islets from 8 weeks old PTP1B 2/2 mice exhibit enhanced glucose-stimulated insulin secretion. Moreover, PTP1B
2/2 mice were able to partially reverse streptozotocin-induced b-cell loss. Together, our data highlight for the first time the
involvement of PTP1B in b-cell physiology, reinforcing the potential of this phosphatase as a therapeutical target for the
treatment of b-cell failure, a central aspect in the pathogenesis of Type 2 Diabetes.
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Introduction
Type 2 Diabetes is currently considered one of the main causes
of morbidity and mortality worldwide. Insulin resistance is a key
characteristic in the development of the disease, and it is defined as
the diminished ability of cells to respond to insulin in terms of
glucose uptake and utilization in peripheral tissues [1]. At the
prediabetic stages, pancreatic b-cell is able to counteract insulin
resistance by increasing insulin secretion in order to maintain
normoglycaemia [2]. However, as the disease progresses, b-cell
compensation fails and b-cell mass is reduced and glucose
homeostasis is disrupted [3,4].
The mechanism underlying the b-cell compensatory response in
humans is still unclear. Evidences from animal studies suggest that
the insulin signalling pathway could be critical for b-cell growth and
survival [5,6]. Insulin signalling is tightly regulated by the
phosphorylation status of several components of the critical nodes
and pathways that control its actions, being relevant both kinases and
phosphatases enzymes [7]. One of the most important phosphatases
regulating the insulin signalling cascade is the protein tyrosine
phosphatase 1B (PTP1B) which inhibits insulin receptor and insulin
receptor substrate 1 by direct dephosphorylation [8]. Previous
studies performed in PTP1B whole body knockout mice (PTP1B
2/2) have revealed that these mice are hypersensitive to insulin and
resistant to weight gain on a high-fat diet [9,10]. Studies using
PTP1B tissue-specific knockout mouse models defined key actions of
this phosphatase to regulate whole body energy and glucose
homeostasis in brain, adipose tissue, liver and muscle [11-14].
Although the beneficial effects of targeting PTP1B in peripheral
tissues are evident the role of PTP1B in pancreatic b-cell is not
fully understood and the information regarding this issue is scarce
[15,16]. In this study, we provide new insights into how PTP1B is
able to regulate important signalling pathways involved in both b-
cell proliferation and survival. We also give evidences about the
role of PTP1B in regulating b-cell mass and function under
physiological and pathological (streptozotocin-induced diabetes)
conditions in vivo. Our results led us to propose that strategies
aimed to antagonize the effects of PTP1B would be beneficial not
only in peripheral tissues but also at the level of pancreatic b-cell.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Animal Ethics/
Research Committee of the University of Barcelona, and
principles of laboratory animal care were followed.
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Cell culture studies
The insulin releasing MIN6 b-cell line was kindly provided by
Dr. Jun-Ichi Miyazaki (Osaka University, Osaka, Japan), and used
between passages 20 and 30 [17]. MIN6 b-cells were maintained
in DMEM containing 25 mmol/l glucose, 10% FBS, 50 Units/ml
Penicillin, 50mg/ml Streptomycin, 2 mM L-glutamine, and 50mM
b-mercaptoethanol. PTP1B silencing was achieved by using a
siGENOME SMART pool, mouse ptpn1 (Thermo Fisher
Scientific, Inc, Waltham, MA, USA) and a scramble siRNA
(Applied Biosystems, Life Technologies Ltd, Paisley PA4 9RF,
UK) as a control. SMARTpoolTM siRNA pools four highly
functional SMART selection designed siRNA targeting the same
gene, minimizing off-target effects. Cells were transfected for 48
hours by using the transfection reagent Metafectene Pro (Biontex,
Martinsried/Planegg, Germany). Transfected MIN6 b-cells were
subsequently used for protein and RNA extraction, and for
performing an in vitro cell proliferation assay.
RNA isolation and quantitative PCR analysis
Total RNA was isolated from transfected MIN6 cells by using
RNeasy Mini Kit (QIAGEN, Hilden, Germany) and quantified
using a Nanodrop 1000 (Thermo Scientific, Wilmington, MA).
RNA was reverse transcribed using High Capacity cDNA Reverse
Transcription Kit (AB Applied Biosystems) following the manu-
facturers instructions. Real time PCR was carried out in Light
Cycler 480 System ((Roche, Basel, Switzerland).) using MESA
GREEN qPCR MasterMix Plus for SYBR Assay (Eurogentec,
Lie`ge, Belgium). mRNA expression levels were determined using
the Standard Curve Method and normalized to the expression of
acidic ribosomal protein 36B4 gene. Primer sequences are the
following: ptpn1 forward: CATCCAGAACATGCA-
GAAGCCGCT and reverse: TTCCCAGCCTTGTCGATCTC;
36B4 forward: GAGGAATCAGATGAGGATATG and reverse:
AAGCAGGCTGACTTGGTTGC. Gene expression in si-ptpn1
MIN6 cells was expressed relative to the mean of the values of the
same gene found in scramble MIN6 cells, set at value 1 as the
reference.
In vitro cell proliferation assay
To assess in vitro cell proliferation in control (Sc) and si-ptpn1
MIN6 cells, we have performed a colorimetric assay based on the
measurement of the incorporation of BrdU, an analogue to
thymidine, during DNA synthesis in proliferating cells. We have
followed manufacturer’s instructions (Cell proliferation ELISA
BrdU Colorimetric, Roche), and we have performed the assay 5
hours after BrdU addition. Experiments with MIN6 cells were
repeated 3 times, each one using 10 replicates; those experiments
performed with dispersed islets cells were repeated 3 times, each
one using 6 replicates.
Mouse model
Wild type (WT) and PTP1B deficient mice (PTP1B 2/2) were
obtained from Abbott Laboratories [10,18]. All experiments were
performed in 8 weeks old male mice littermates, on a mixed
C57BL/6Jx129 background. The animals were housed with a 12-
h light/12-h dark cycle in temperature and humidity-controlled
environment in animal facility with free access to water and
standard laboratory chow.
Islet studies
Animals were sacrificed by cervical dislocation after being fully
anesthetized by ketamine-xylacine. After direct puncture of the
common bile duct, a collagenase solution was perfused to digest
the pancreas, and islets were purified using Histopaque gradient
[19]. Islets were handpicked under a stereomicroscope and
separate batches of 8 islets were used to determine insulin
secretion and content in static incubation assays as previously
described [20]. Insulin was measured by using a mouse insulin
ELISA kit (Mercodia). We have performed four different
experiments. In each one we have pooled islets from two WT or
two PTP1B 2/2 mice, as we need at least 80 islets (similar in size)
per genotype to incubate the different batches with low and high
glucose concentrations.
Pancreas morphometry and immunolocalization
procedures
Pancreases were obtained, fixed overnight in 10% formalin and
paraffin-embebed. Three non-consecutive 4-mm thick pancreatic
sections 150 mm apart (six sections/animal) were labelled with a
standard immunofluorescence method for paraffin sections.
Primary antibodies used were: guinea pig anti-insulin IgG
(1:1000 dilution, Dako, Glostrup, Denmark) and rabbit anti-
glucagon IgG (1:500 dilution, Dako). Cy3 anti-guinea pig and Cy2
anti-rabbit labelled secondary antibodies (1:500 dilution, Jackson
Immunoresearch, Suffolk, UK) were used. Hoescht (1:500
dilution, Sigma-Aldrich) was employed as nuclear marker. Images
were taken with a Leyca DMR HC epifluorescence microscope.
For morphometric analysis, at least 100 islets from both genotypes
were manually traced and analyzed using Image J (National
Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.gov/
ij/) software. a and b-cell mass were quantified blindly as a and b-
cell volume density respectively, multiplied by pancreas weight
[21].
An immunofluorescence approach was employed in order to
study subcellular localization of FOXO1 in islets. For this
experiment, primary antibodies used were: guinea pig anti-insulin
IgG (1:1000 dilution, Dako) and rabbit anti-FOXO1 IgG (1:20
dilution, Cell Signaling, Beverly, MA, USA). Cy3 anti-guinea pig
and Cy2 anti-rabbit labelled secondary (1:500 dilution, Jackson
Immunoresearch) antibodies were used. Hoescht antibody (1:500
dilution, Sigma-Aldrich) was used as nuclear marker. Images were
taken as described above and analyzed using Image J software.
The results are expressed as the number of b-cells co-expressing
insulin and total/nuclear FOXO1.
b-cell proliferation and apoptosis measurements
Three non-consecutive 4-mm sections were deparaffinised,
rehydrated and treated with citrate buffer (10 mmol/l; pH 6.0)
as antigen retrieval. Slides were immunostained with purified
mouse anti-ki67 antibody (1:50 dilution, BD Pharmigen, San Jose,
CA, USA), and cleaved caspase-3 (1:400 dilution, Cell Signaling)
in order to study proliferation and apoptosis respectively. At least
3000 beta cells per sample were counted. Co-localization with
insulin positive b-cells was checked individually. Image analysis
was performed as stated above. The results are expressed as the
number of b-cells co-expressing insulin and ki67 or cleaved
caspase-3.
Western Blot
Protein extracts from islets and MIN6 transfected cells were
prepared in lysis buffer (50 mmol/l Tris pH 7.5, 5 mmol/l EDTA,
150 mmol/l NaCl, 1% Triton X-100, 10 mmol/l sodium
phosphate) containing fresh protease and phosphatase inhibitor
cocktails (Roche, Basel, Switzerland). Proteins were separated by
8% SDS-PAGE and transferred to nitrocellulose membranes.
Immunoblots were performed using the following antibodies:
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rabbit monoclonal anti-PTP1B antibody (Novus Biologicals,
Littleton, CO, USA), rabbit anti-STAT3 antibody, rabbit anti-
pSTAT3Tyr705 antibody, rabbit anti-AKT IgG, rabbit anti-
pAKTThr308 antibody, rabbit anti-ERK1/2 (p44/42 MAPK)
antibody, rabbit anti-pERKThr202/Tyr204 antibody, rabbit anti-
FOXO1 IgG, rabbit anti-p FOXO1Ser256 antibody (all of them
from Cell Signaling) and mouse monoclonal anti-p53 antibody
(ABCAM, Cambridge, UK). As a loading control, rabbit anti-actin
antibody was used (Sigma Aldrich). The antibody dilution used
was 1:1000.
Immunoblots were developed with horseradish peroxidise-
conjugated secondary antibodies (GE Healthcare Bio-Sciences
Corp. Piscataway, NJ, USA) and visualized using enhanced
chemiluminiscence (Thermo Fisher Scientific Inc. Waltham, MA,
USA). Bands were detected by an ImageQuant LAS 4000 camera
(GE Healthcare) and quantified by densitometry scanning with
Image J software.
Intraperitoneal glucose tolerance test
In order to assess glucose tolerance, intraperitoneal glucose
tolerance tests (ipGTT) were performed after overnight fasting in
PTP1B 2/2 and WT mice with free access to water. The ipGTT
was performed by the administration of an injection of D-glucose
(2 g/Kg body weight), and blood samples were collected from tail
vein at 0, 15, 30, 60 and 120 minutes after injection. Glycaemia
was measured at the same time points using a clinical glucometer
and Accutrend Check test strips (Roche Diagnostics, Switzerland).
Plasma was obtained by blood centrifugation and kept at 280uC
for insulin determination using a mouse insulin ELISA kit
(Mercodia, Uppsala, Sweden).
Diabetes induction
Diabetes was induced in 4-6 hours fasted 8 weeks-old male mice
by a single intraperitoneal injection of 125 mg/Kg streptozotocin
(STZ, Sigma-Aldrich, St Louis, MO, USA) diluted in 0.9% NaCl
with 100 mmol/l sodium citrate (pH 4.5). The animals were
monitored daily for hyperglycaemia for 6 days, and those mice
that had an average of plasma blood glucose levels above 250 mg/
dl were considered for the experiment. After the application of the
selection criteria, mice were monitored weekly for seven weeks,
measuring blood glucose levels. At the time of sacrifice, 7 weeks
after the streptozotocin injection, pancreas samples were excised
and conserved for performing further morphometric and prolif-
erative/apoptotic studies, as described above.
Statistical analysis
All the results are expressed as mean6SEM. Differences
between experimental groups were determined by Students t-test.
p,0.05 was considered statistical significant.
Results
PTP1B modulates proliferation in pancreatic b-cells
In order to determine whether PTP1B regulates b-cell mass, we
silenced this phosphatase in the mouse pancreatic b-cell line MIN-
6 using siRNA (si-ptpn1). 100 nM of siRNA was effective in
silencing PTP1B mRNA expression by 76% (Figure 1A) and
reduce PTP1B protein content by 59% (Figure 1B) in MIN-6 cells
compared with the scramble si-RNA (Sc). Our examination of si-
ptpn1 MIN6 cells showed a significantly increased proliferative
rate on those cells when assessed by measuring in vitro BrdU
incorporation (Figure 1C). Interestingly, we have confirmed the
role for PTP1B 2/2 in regulating islet cell proliferation in
dispersed islets from PTP1B 2/2 and WT mice by performing the
same experiments of in vitro incorporation of BrdU in this setting
(Figure 1D).
PTP1B regulates changes in islet morphometry
As we have stated above, it seems clear that PTP1B plays a
determinant role in pancreatic b-cell proliferation. Therefore, to
confirm our findings we next performed ex vivo morphometric
analysis of pancreases embedded in paraffin, both from PTP1B
2/2 and WT mice. On this regard, islets from PTP1B 2/2 mice
also exhibited higher b-cell proliferation (Figure 2A), measured by
ki67 co-expression with insulin. Interestingly, b-cell apoptosis was
lower in islets from PTP1B 2/2 mice compared to WT islets
(Figure 2B), measured by cleaved-caspase3 co-expression with
insulin.
Proliferation and apoptosis are important molecular mecha-
nisms determining cellular mass. Although no differences in
pancreas weight were observed when normalized by body weight
(Figure 2C), the morphometric analysis of the pancreas showed a
higher number of islets in PTP1B 2/2 versus WT littermate mice
(Figure 2D). A more detailed study of islet size showed that the
increase in islet area from PTP1B 2/2 mice is mainly due to a
higher number of small islets (,1000 um2) (Figure 2E). We have
also observed a significantly increase in b-cell mass in PTP1B 2/2
when compared with WT mice (Figure 2F). The a-cell mass
showed a tendency to be increased in PTP1B 2/2 mice, although
this difference didn’t achieve statistical significance (Figure 2G).
PTP1B modulates signalling pathways involved in the
regulation of beta cell mass in isolated pancreatic islets
After establishing a role for PTP1B in the regulation of b-cell
proliferation, we further assess the potential molecular mecha-
nisms responsible for these changes in MIN6 cells and islets from
PTP1B 2/2 and WT mice. As PTP1B is a main negative regulator
of insulin signalling, it would be feasible to think that its ablation
could affect key proteins of the different pathways regulated by
insulin involved in b-cell proliferation and apoptosis [7,22,23]. On
this regard, we found that AKT and ERK1/2 phosphorylation
were significantly increased in si-ptpn1 MIN6 cells (Figure 3B and
3C). Similar results were found when we analyzed STAT3, AKT
and ERK1/2 phosphorylation in pancreatic islets; all of them
showed the same pattern described in MIN6 cells as its
phosphorylation status is significantly increased in islets from
PTP1B 2/2 mice when compared to their WT littermates
(Figure 3D-F). On the other hand, we assessed the expression of
the pro-apoptotic protein p53 which was significantly decreased in
islets from PTP1B 2/2 mice (Figure 3G), which supports the role
played by PTP1B not only in the control of cell proliferation but
also in regulating cell apoptosis (Figure 2A and 2B).
Likewise, we have studied the insulin stimulated AKT/FOXO1
signalling, which could be involved in regulating proliferation
and/or apoptosis in b-cells downstream of PTP1B [16,24].
Immunohistochemical analysis of pancreatic islets showed that
FOXO1 positive b-cells were significantly reduced in PTP1B 2/2
mice when compared with their respective WT littermates
(Figure 3H). Moreover, regulation of the nuclear/cytoplasmic
distribution of FOXO1 is important in determining its biological
activity in metabolism, cellular proliferation and survival rather
than protein abundance per se. We found that FOXO1 nuclear
localization was reduced in PTP1B 2/2 islets (Figure 3I and 3J),
concomitantly with an increased FOXO1 phosphorylation at
Ser256 (Figure 3K).
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PTP1B regulates b-cell insulin secretion in isolated islets
and improves glucose tolerance and insulin response in
vivo
Our next aim was to see whether PTP1B actions on b-cell have
an effect on insulin secretion; for such purpose we undertook
studies both in vitro and in vivo. In vitro basal insulin secretion (2.8
mM glucose) was lower in PTP1B 2/2 than in WT islets
(Figure 4A), although after normalizing by insulin content, which
was similar between PTP1B 2/2 and WT pancreatic islets
(Figure 4B), insulin secretion does not achieve statistical signifi-
cance (Figure 4C) (p = 0.06). When islets were stimulated with high
glucose concentrations (16.7 mM glucose) PTP1B 2/2 islets
secreted significantly more insulin than the islets from their WT
littermates (Figure 4A and 4C). These in vitro observations suggest
that PTP1B could directly modulate insulin secretion, although
paracrine effects from other cell types within the islet cant be ruled
out. Our in vivo experiments showed that PTP1B 2/2 mice were
hypoinsulinemic after an overnight fasting and that at 30 minutes
during ipGTT plasma insulin levels were significantly higher in
PTP1B 2/2 mice (Figure 4D), in line with our in vitro studies. This
is consistent with the higher glucose tolerance observed in PTP1B
2/2 mice, as reflected by differences in glycaemia during an
intraperitoneal glucose tolerance test (ipGTT) (Figures 4E, F).
These differences in glucose handling are in agreement with
previous observations performed in peripheral tissues [9,10]. In
summary, our in vitro and in vivo islet results led us to conclude that
the absence of PTP1B alters pancreatic b-cell performance by
increasing insulin secretion under glucose stimulated conditions.
PTP1B ablation alleviates streptozotocin-induced b-cell
damage
Administration of streptozotocin (STZ) to mice causes damage
and loss of b-cells leading to a chronic hyperglycaemic state. This
model has been used as a model of b-cell regeneration as partial
recovery of b-cell mass can be reached under certain conditions
[25]. Given our previous results demonstrating an effect of PTP1B
on b-cell proliferation and apoptosis, we tested whether the
absence of PTP1B could potentiate b-cell mass recovery. STZ
treatment was effective in inducing diabetes both in PTP1B 2/2
and WT mice, based on the high blood glucose levels observed
during the first 6 days of treatment (above 250 mg/dl, inclusion
criteria). Hyperglycaemia was significantly lower in STZ-treated
PTP1B 2/2 mice than in STZ-treated WT littermates (Figure 5A)
along the 7 weeks of the experimental period. The absence of
PTP1B also ameliorates the decrease in body weight caused by the
diabetic state (Figure 5B and C), measured at the end of the
procedure, when mice were 15 weeks of age. Pancreas weight
shows no differences between STZ-treated PTP1B 2/2 and WT
mice (Figure 5D).
Figure 1. Ablation of PTP1B increases proliferation in in vitro transfected MIN6 cells and dispersed islet cells. A) mRNA expression and
B) protein content are used to confirm the efficiency of PTP1B siRNA transfection and silencing in MIN6 cells. Values are expressed relative to 36B4 as
a housekeeping gene and actin protein content respectively. C) In vitro BrdU incorporation in proliferating si-ptpn1 MIN6 cells. Represented values
are normalized to scrambled siRNA (Sc) MIN6 cells; n = 3 different experiments, 10 replicates per group each experiment. D) In vitro BrdU
incorporation in PTP1B 2/2 proliferating dispersed islet cells is expressed relative to WT; n = 3 different experiments, 6 replicates per group each
experiment. All bars represent mean6SEM * p,0.05, ** p,0.005 PTP1B 2/2 vs WT.
doi:10.1371/journal.pone.0090344.g001
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Figure 2. Ablation of PTP1B increases proliferation in in vivo b-cells and alters pancreas morphometry in PTP1B 2/2 mice.
Morphometric analysis of fixed paraffin embedded pancreas from PTP1B 2/2 and WT mice (n = 5–7 animals per group). A) Level of proliferating b-
cells (ki67+/insulin+) from PTP1B 2/2 and WT mice. Representative images showing immunostaining for ki67 (green), insulin (red), and merged
images together with Dapi for nuclei (blue) on pancreatic sections from PTP1B 2/2 and WT mice. B) Levels of apoptotic b-cells (caspase3+/insulin+)
from PTP1B 2/2 and WT mice. Representative images showing immunostaining for insulin (red), Caspase3 (green), and Dapi for nuclei (blue) on
pancreatic sections from PTP1B 2/2 and WT mice. C) Pancreas weight normalized by body weight. D) Number of islets, over the total pancreatic area
(mm2) studied. E) Distribution of islets on the basis of their size, expressed as the percentage of a given size, over the total pancreatic area (mm2)
studied. F) b-cell mass is quantified blindly as b-cell volume density, multiplied by pancreas weight. G) a-cell mass is quantified blindly as a-cell
volume density, multiplied by pancreas weight. All bars represent mean6SEM * p,0.05 PTP1B 2/2 vs WT.
doi:10.1371/journal.pone.0090344.g002
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To study whether the improvement in glycaemia observed in
STZ-treated PTP1B 2/2 mice was due to a specific effect in the
pancreas, we performed morphometric studies in fixed pancreas
from STZ-treated WT and PTP1B 2/2 mice 7 weeks after STZ
injection. b-cell mass was significantly higher in STZ-treated
PTP1B 2/2 mice (Figure 5E) when compared with islets from
STZ-treated WT littermates. This increase in b-cell mass is
consistent with the observed increase in b-cell proliferation
(Figure 5F) in STZ-treated PTP1B 2/2 mice. Moreover, b-cell
apoptosis was decreased in islets from STZ-treated PTP1B 2/2
mice when compared with STZ-treated WT littermates
(Figure 5G). Thus, we have also demonstrated that deletion of
PTP1B could improve b-cell mass and survival in an animal model
of diabetes.
Figure 3. Pro-proliferative/pro-survival signalling in in vitro si-ptpn1 MIN6 cells and in isolated pancreatic islets from 8 weeks old
PTP1B 2/2 mice. A-C) Western blot of phospho-STAT3Tyr705, phospho-AKTThr308 and phospho-ERK1/2Thr202/Tyr204 in transfected MIN6 cells.
Representative immunoblot for each phosphorylated and total protein is shown. n = 3 per group. Bands are quantified by densitometry and values
expressed as the ratio of each phosphorylated form relative to the total protein expression. D-G) Representative immunoblots and quantification for
phospho-STAT3Tyr705, phospho-AKTThr308, phospho-ERK1/2Thr202/Tyr204 and p53 in isolated islets from PTP1B 2/2 and WT mice. Bands are quantified
by densitometry and values expressed as the ratio of each phosphorylated form relative to the total protein expression (immunoblots for total STAT3,
AKT and ERK1/2 are also shown, together with actin in the case of p53). H) Levels of FOXO1 protein expression in b-cell, determined by
immunofluorescence analysis. I) FOXO1 nuclear localization in islets is represented over the total pancreatic area (mm2) studied. J) Representative
images of FOXO1 in WT and PTP1B 2/2. K) Quantification and representative immunoblot for phospho-FOXO1Ser256 in isolated islets from PTP1B 2/2
and WT mice. n = 6 animals per group. All bars represent mean6SEM * p,0.05, ** p,0.005 si-ptpn1 vs Sc or PTP1B 2/2 vs WT.
doi:10.1371/journal.pone.0090344.g003
Figure 4. Glucose induced insulin secretion both in vivo and in isolated islets from PTP1B 2/2 and WT mice. Islets were isolated from 8
weeks old WT and PTP1B 2/2 mice and insulin secretion was assayed at indicated glucose concentrations (2.8 and 16.7 mM) in static incubation
experiments as indicated in materials and methods section. A) Insulin secretion per islet. B) Islet insulin content. C) Insulin secretion as a percentage of
total insulin content. D) Plasma insulin levels after glucose administration during an ipGTT test in PTP1B 2/2 (n = 5) and WT (n= 5) mice. E) Glucose
tolerance test (ipGTT): blood glucose levels of PTP1B 2/2 (n = 13) and WT (n= 12) mice at the indicated time points after an intraperitoneal injection
of glucose (2 g/Kg body weight). F) ipGTT area under the curve (AUC). AUC was calculated using the trapezoidal rule. All results represent mean6SEM
* p,0.05; ** p,0.005 PTP1B 2/2 vs WT.
doi:10.1371/journal.pone.0090344.g004
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Discussion
PTP1B plays a major role in several physiological functions
including energy balance and the regulation of glucose homeo-
stasis [26–28], hence it is a potential target for the treatment of
Diabetes. On this regard, much effort has been done in order to
describe the role of PTP1B in peripheral tissues [11–14,29], but
information about its role in endocrine pancreas is limited [15,16].
To our knowledge, this is the first study showing that PTP1B
modulates b-cell mass in a cell autonomous manner through the
regulation of key signalling pathways involved in b cell prolifer-
ation and apoptosis.
This work shows a higher ERK1/2 and AKT phosphorylation
in the b-cell line MIN6 once PTP1B is silenced, as well as in
isolated islets from PTP1B 2/2 mice. Once ERK1/2 is activated
it translocates to the nucleus, where through interaction with
transcription factors regulates cell proliferation and survival [30].
Activation of AKT by insulin signalling has also been linked to b-
cell survival [31,32] and to the degradation by the proteasome of
the pro-apoptotic protein p53 [33]. A plausible explanation for the
mitogenic effect of AKT activation is that this kinase phosphor-
ylates and inactivates the transcription factor forkhead box O1
(FOXO1), which negatively regulates b-cell formation and
function. FOXO1 transcriptional activity is inhibited via nuclear
exclusion [34–39], and its phosphorylation is believed to be one of
the main anti-apoptotic signals downstream of AKT [40].
Although its role in b-cell is currently under debate [41], our
results are in agreement with those of Folli et al. [39], as we here
show that FOXO1 nuclear localization is reduced in b-cells from
PTP1B 2/2 mice concomitantly with an increased phosphoryla-
tion of FOXO1 at residue Ser256 in islets from PTP1B 2/2 mice
[42]. Folli et al. [39] showed that when disrupting insulin signalling
in b-cell (bIRKO mice), FOXO1 locates mainly in the nucleus,
avoiding cell cycle progression and leading to a reduction in b-cell
mass. Our novel data about the role played by PTP1B in b-cell
proliferation are in agreement with previous observations in
hepatocytes showing that this phosphatase regulates multiple
signalling pathways that trigger proliferation in response to a
partial hepatectomy [43].
Our results showed that the increase in AKT phosphorylation is
in line with a decrease in the expression of p53 protein in PTP1B
2/2 islets. In addition, p53 expression is regulated via the JAK2/
STAT3 signalling pathway, which is in turn negatively regulated
by PTP1B [44]. Thus, it has been shown that the dephosphor-
ylation of p-STAT3 by PTP1B lead to the stabilization of p53
expression and apoptosis [45]. We here suggest that the
combination of AKT activation and the increased phosphorylation
of STAT3, facilitated by the lack of PTP1B, allows a decrease in
p53 protein level, which partially explain the lower beta cell
apoptosis described in PTP1B 2/2 islets. These results are in
accordance with the higher b-cell proliferation observed both in si-
ptpn1 MIN6 cells and isolated islets from PTP1B 2/2 mice.
Our studies regarding in vivo glucose homeostasis in 8 weeks-old
PTP1B 2/2 male mice unravelled an enhanced insulin secretion
during the ipGTT. These results correlate with the higher glucose-
stimulated insulin release observed in isolated pancreatic islets
from those mice, and are in agreement with a previous report
performed in rat islets, in which in vitro silencing of PTP1B leads to
an increase in insulin release [46]. Moreover, pancreas morpho-
metric analyses have revealed a higher b-cell mass in PTP1B 2/2
than in WT mice. A detailed study of these islets led us to conclude
that the increase in b-cell mass is due to a significantly higher
number of the smallest islets (under 1000mm2) in PTP1B 2/2 than
in WT mice. Together, these results confirm that the effect of
PTP1B in b-cell is cell autonomous, and independent of the higher
whole body insulin sensitivity observed in PTP1B 2/2 mice at 8
weeks of age. However, unpublished results in our laboratory
regarding glucose homeostasis and pancreas morphometry in
PTP1B 2/2 mice at 15 weeks are in agreement with previous
studies [15,16] which have evaluated b-cell morphometry in
PTP1B 2/2 mice showing no differences between pancreatic b-
cell cross-sectional area of 12 and 15 weeks old PTP1B 2/2 and
WT mice. These results seem to indicate that the higher peripheral
insulin sensitivity observed in PTP1B 2/2 mice is not able to
counteract the effect of the absence of PTP1B on b-cell physiology
until later ages.
To investigate the potential role of PTP1B in the mechanisms
involved in the characteristic b-cell loss associated with the
progression of diabetes, we used the streptozotocin-induced
pancreatic injury model, as a way to evaluate the effect of a
stable hyperglycaemic state. Plasma glucose levels are significantly
lower in PTP1B 2/2 mice after streptozotocin-induced diabetes.
This moderate improvement in glucose handling could be
explained by a higher b-cell mass in PTP1B –/– mice due to a
higher rate of b-cell replication, measured at the end of the
experimental period, 7 weeks after the streptozotocin injection. In
addition to this, PTP1B ablation may be involved in protecting b-
cells from glucotoxicity-induced apoptotic cell death, as shown by
our caspase3 immunostaining analysis. These results are in line
with a previous report where deletion of PTP1B is able to partially
recover b-cell damage induced by the genetic ablation of IRS2, a
model of genetically induced Type 2 Diabetes [15].
In summary, our results support the notion that PTP1B is a
critical regulator of b-cell physiology both at the level of b-cell
mass and function. The information presented in this manuscript
led us to propose PTP1B as a potential target for the treatment of
b-cell dysfunction, critical in Type 2 Diabetes aetiology. More-
over, our data underscore the importance of future studies aimed
to further delineate PTP1B actions in pancreatic b-cell.
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